Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Buy Nerlynx (neratinib) Online • Price & Costs | TheSocialMedwork
New company Puma roars with Pfizer licensing deal
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Acquires Global Rights to Pfizer's Phase III Breast Cancer Drug Neratinib
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - ScienceDirect
Puma Biotechnology
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
Puma Biotechnology - Wiki
CHMP recommends approval of Puma's breast cancer drug Neratinib - Pharmaceutical Business review
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects
New early breast cancer drug now approved in Malaysia
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers - ScienceDirect
New Breast Cancer Medicines & Drugs | TheSocialMedwork
Frontiers | Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Neratinib
Neratinib - Wikipedia
Neratinib (HKI-272) | HER2/EGFR Inhibitor | MedChemExpress
Puma Biotech up more than 270% in one day
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects
Puma and CANBridge cancel licensing deal for $20m
PDF) How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
